About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Monday, August 18th, 2014

The QualityStocks
Daily Stock List


Cloud Medical Doctor Software Corp. (NSCT)

HotStockProfits, Wallstreet Profiler, PennyDoctor, StockRunway, Value Penny Stocks, Ascending Stocks, Nebula Stocks, OTC Picks, Stock Traders Chat, and MicrocapVoice reported on Cloud Medical Doctor Software Corp. (NSCT), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Henderson, Nevada based Cloud Medical Doctor Software Corp. (Cloud-MD) is a leading provider of "Cloud Based" Medical Practice Management Business solutions and a provider of Digital Electronic Security (DES) solutions. Its solutions are designed by doctors for doctors. Cloud-MD has three goals: increasing individual practice income; creating personal investment value; and regaining influence over the way medicine is practiced and administrated. Cloud-MD’s shares trade on the OTC Markets’ OTCQB.

Cloud-MD has a fully integrated and interoperable suite of software-as-a-service (SaaS) products and medical practice services. These provide the foundation for its Revenue Cycle Management capabilities. In addition, the Company provides the installation, training, and support of these systems.

Cloud-MD offers a complete collection of integrated Practice Management (PM), Revenue Management (RM), Patient Profile Management (PPM) and Medical Billing Services (PBS) solutions. These meet all of the major needs of healthcare providers. Cloud-MD has over three decades of billing experience and more than $1 billion in medical claims processed.

Cloud-MD announced at the end of June that it closed a contract for its first customer to utilize its patented new data-at-rest and data-in-motion technology. All of these advances are based on the Company’s CipherLoc™ technology set. Cloud-MD announced in July that Gawk, Inc. (GAWK) signed a contract to utilize Cloud-MD’s patented pending new data-at-rest and data-in-motion technology. Gawk signed a contract with Cloud-MD’s CipherShop division, valued at $1,125,000. Gawk is a world innovator of self-service global digital distribution.

In addition last month, Cloud-MD announced that its soon-to-be-released Cloud+MD Office 2.0 will soon receive industry Meaningful Use Stage 2 (MU2) certification. Cloud+MD Office 2.0 is a "Cloud Based", fully integrated and interoperable suite of medical software and services. The design of it is by experienced healthcare analysts and programmers for healthcare providers, which produces "Actionable Information" to help Independent Physician Practices, New Care Delivery Models (ACO), Healthcare Systems as well as Billing Services optimize a broad assortment of business processes. The MU2 final rules define a common dataset for all summary of care records. This includes an impressive array of structured and coded data to be formatted uniformly and sent securely during transitions of care.

Last week, Cloud-MD announced 2014's Q3 revenue increase of 716.81 percent over 2013's Q3. This marks the completion of the transition from development stage to commercial stage for the Company’s CipherShop Division. According to Cloud-MD executives, sales for Q3 2014 totaled $1,126,725, mainly resulting from its Cloud-MD's CipherShop division that features its CipherLoc™ Polymorphic Key Progression Algorithmic Cipher Engine.

Cloud Medical Doctor Software Corp. (NSCT), closed Monday's trading session at $0.04, down 13.04%, on 1,604,306 volume with 101 trades. The average volume for the last 60 days is 296,526 and the stock's 52-week low/high is $0.011/$0.10.

Advanced Medical Isotope Corp. (ADMD)

SmallCapVoice reported recently on Advanced Medical Isotope Corp. (ADMD), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.

Advanced Medical Isotope Corp. involves in the production and distribution of medical isotopes. Medical isotopes (radioisotopes) are used in molecular imaging, therapy, and nuclear medicine to diagnose, manage, and treat diseases. Based in Kennewick, Washington, the Company is essentially a late stage development business engaged mainly in the development of brachytherapy devices and medical isotopes for diagnostic and therapeutic applications. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area. Advanced Medical Isotope’s shares trade on the OTC Markets’ OTCQB.

The Company has centred on the commercialization of medical isotope technologies since 2006. It has explored technologies for the production of medical isotopes and medical applications of isotope technologies. This includes a line of brachytherapy products incorporating patented technology licensed exclusively to the Company by Battelle Memorial Institute, developed at Pacific Northwest National Laboratory.
Advanced Medical Isotope’s team consists of radio-chemists, scientists, and engineers. The Company’s team collaborates with national labs and universities to implement proprietary technologies capable of producing essential medical isotopes on U.S. soil. Advanced Medical Isotope is engaging in the development, production, and distribution of medical isotopes focused on yttrium-90 brachytherapy devices.

The Company is developing medical isotope technologies, which are changing the practice of medicine and transforming the standard of medical care. Its objective is to empower physicians, medical researchers, and ultimately, patients, through providing them with vital medical isotopes to detect, manage, and cure human disease, and improve the lives of patients.  
Advanced Medical Isotope employs innovative production methods to offer a broad variety of reliable, domestically produced medical isotopes and in vivo delivery systems. The specific isotopes required are in short supply and must be created. The most common radioisotope used in diagnosis is technetium-99.  

The Company employs a proton linear accelerator (PULSAR®) manufactured by AccSys Technology, Inc. It has targeted this compact isotope production system as its first differentiated technology. The Company’s medical isotope products include stable isotopes, radio pharmaceuticals, and radio chemicals. Future isotopes include Indium-111; Iodine-124; Strontium-82/Rubidium-82 generators; Germanium-68/Gallium-68 generators, as well as Actinium-225/Bismuth-213 generators.

In July, Advanced Medical Isotope announced that Battelle acquired approximately 11 percent of Advanced Medical Isotope’s outstanding Common Stock. Battelle is a leading global science and technology enterprise. Battelle explores emerging areas of science and develops and commercializes technology. 

Advanced Medical Isotope Corp. (ADMD), closed Monday's trading session at $0.0115, down 17.86%, on 4,069,165 volume with 45 trades. The average volume for the last 60 days is 1,024,882 and the stock's 52-week low/high is $0.01/$0.125.

Liquidmetal Technologies, Inc. (LQMT)

PennyStocks24, SuperNova Elite, Wealth Daily, PennyStocks Forever, Jason Bond, and Greenbackers reported earlier on Liquidmetal Technologies, Inc. (LQMT), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Headquartered in Rancho Santa Margarita, California, Liquidmetal Technologies, Inc. is the foremost developer of amorphous alloys and composites, which use the performance advantages that amorphous alloy technology offers. Amorphous alloys are unique materials distinguished by their ability to retain a random structure when they solidify. This is in contrast to the crystalline atomic structure that forms in ordinary metals and alloys. Liquidmetal has two to three times the strength of titanium and stainless steel. They undergo processing similar to plastics on the Company's proprietary Liquidmetal molding machines. Liquidmetal Technologies lists on the OTC Bulletin Board.

The Company is the first business to produce amorphous alloys in commercially viable bulk form. This is permitting key improvements in products across a broad array of industries. Its class of patented alloys and processes form the foundation of high performance materials used in an extensive assortment of medical, military, consumer, and industrial, and sporting goods products.

Liquidmetal Technologies controls the intellectual property (IP) rights with over 50 U.S. patents. The Company’s alloys are, in a number of cases, stronger, harder, more elastic, and more wear and corrosion resistant than normally used high-performance alloys. Liquidmetal is processed and solidified in a vitreous or amorphous state (frozen liquid). Liquidmetal Technologies’ "bulk" amorphous alloys possess advantages normally associated with plastics. This includes the ability to undergo molding into precision, complex, and highly finished products.

Recently, Liquidmetal Technologies announced that it, and the University of Southern California’s M.C. Gill Composites Center, are joining forces to develop an advanced manufacturing process to produce large-scale amorphous metal and fiber laminate sheets for space applications. The work is funded by a NASA SBIR (Small Business Innovation Research) Phase I contract addressing solicitation topic number Z2.01, “Cross cutting advanced manufacturing process for large scale bulk metallic glass systems for aerospace applications.”

Last week, Liquidmetal Technologies reported results for the quarter ended June 30, 2014. It generated revenues of $153,000 as it continued to concentrate on the development of prototype and commercial parts for its customers and partnering with licensees on the development of the Company’s technology and production processes. Cash totaled $13.9 million at June 30, 2014, versus $2.1 million at December 31, 2013. During Q2 2014, Liquidmetal Technologies began its direct efforts to advance the commercialization of its technology.

Liquidmetal Technologies, Inc. (LQMT), closed Monday's trading session at $0.2425, down 0.61%, on 1,255,279 volume with 184 trades. The average volume for the last 60 days is 4,693,255 and the stock's 52-week low/high is $0.1115/$0.408.

Thinspace Technology, Inc. (THNS)

RedChip, PennyStocks24, TheBombPennyStocks, Pumps and Dumps, and Stocks To Watch reported recently on Thinspace Technology, Inc. (THNS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Thinspace Technology, Inc. is an international provider of reliable, scalable, and affordable application delivery, virtualization, and cloud client technology. It provides this technology to public and private sector companies and organizations of all sizes. The Company’s list of private and public sector customers include NASA, PWC, Deutsche Bank, Toyota, and, NHS, local councils, universities, schools, and housing associations. Thinspace Technology is based in Port Orange, Florida. The Company lists on the OTCQB.
Thinspace offers its Propalms TSE. This is an application delivery solution, which allows windows applications and desktops to be managed centrally and delivered to users on demand, and to any device regardless of location. Propalms TSE enhances Windows® Remote Desktop Services (RDS). It provides an on-demand application delivery platform effectively bridging the gap between native RDS and Citrix.

In addition, the Company offers its Pano for VDI. The Pano solution includes everything required to deploy virtual desktops on top of VMware or Microsoft virtualization platforms. In one integrated system, users get a choice of Thinspace’s innovative award-winning Pano zero client, the new Pano Virtual Client for repurposed PCs/Laptops, and Pano Remote for secure remote access from anywhere.

Moreover, Thinspace Technology’s products include OneGate. This is an application gateway that provides secure remote access to applications using standards based SSL encryption. Thinspace also offers Universal Client. It provides access to applications or Windows desktops from one’s iPad, iPhone, or Android tablet or Smartphone.

Thinspace Technology announced recently that Mr. Jay Christopher Bautista was appointed CEO of the Company. Mr. Bautista will also be appointed to Thinspace’s Board of Directors, effective upon the Company's meeting its information obligations under the Securities Exchange Act of 1934, as amended. Mr. Bautista has an extensive background in management consulting and technology expertise. Most recently, he served as a Principal at Infosys Ltd. Infosys is a top technology company. It pioneered the Global Delivery Model of technology solutions.

Today, Thinspace Technology announced its Q2 2014 financial and operational results. Net revenue was $2.593 million. This represents an increase of 871 percent from $0.267 million in Q2 2013, and an increase of 230 percent from $0.784 million recorded in Q1 2014. Gross profit for the quarter ended June 30, 2014 was $0.865 million, up 865 percent, falling in line with revenue gains over the same period of the year prior.

Thinspace Technology, Inc. (THNS), closed Monday's trading session at $0.105, even for the day, on 19,850 volume with 6 trades. The average volume for the last 60 days is 36,204 and the stock's 52-week low/high is $0.09/$0.99.

Amarantus Bioscience Holdings, Inc. (AMBS)

Pumps and Dumps, SmallCapVoice, Streetwise Reports, PennyStocks24, SuperNova Elite, and Penny Stock Pinnacle reported recently on Amarantus Bioscience Holdings, Inc. (AMBS), and we choose to report on the Company today, here at the QualityStocks Daily Newsletter.

OTCQB-listed Amarantus Bioscience Holdings, Inc. is a biotechnology company focusing on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis. It is developing certain biologics surrounding the intellectual property (IP) and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Alzheimer's disease, Traumatic Brain Injury, and other human diseases. The Company has an exclusive global license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease. Founded in 2008, Amarantus Bioscience has its head office in San Francisco, California.

In addition, the Company has also licensed Eltoprazine, a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. Furthermore, it owns the IP rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (MANF). Amarantus is developing MANF-based products as treatments for brain disorders. Its lead therapeutic program MANF is a targeted therapeutic to address the underlying Programmed Cell Death (Apoptosis) associated with a broad variety of devastating human disorders.

Amarantus has an exclusive worldwide license to the Lymphocyte Proliferation test (LymPro Test®) for Alzheimer's disease. The Company additionally owns IP for the diagnosis of Parkinson's disease (NuroPro) and the discovery of neurotrophic factors (PhenoGuard).

The Company is a Founding Member of the Coalition for Concussion Treatment (#C4CT). This movement began in collaboration with Brewer Sports International (BSI). It is working to raise awareness of new treatments in development for concussions and nervous-system disorders.

Last Friday, Amarantus Bioscience announced that it exercised its exclusive option to license IP related to MANF's utility in treating retinal disorders from the University of Miami's Bascom Palmer Eye Institute. The Company has entered into an exclusive license for this IP. With this agreement, Amarantus Bioscience has been granted a perpetual, exclusive worldwide license to IP, covering the use of MANF for the treatment of retinal disorders. This includes Retinitis pigmentosa.

Amarantus Bioscience Holdings, Inc. (AMBS), closed Monday's trading session at $0.1247, up 8.53%, on 9,421,657 volume with 485 trades. The average volume for the last 60 days is 10,407,554 and the stock's 52-week low/high is $0.032/$0.196.


The QualityStocks
Company Corner


Alliance Creative Group (ACGX)

The QualityStocks Daily Newsletter would like to spotlight Alliance Creative Group (ACGX). Today, Alliance Creative Group closed trading at $0.0035, off by 5.41%, on 4,330,918 volume with 32 trades. The stock’s average daily volume over the past 60 days is 5,887,423, and its 52-week low/high is $0.0007/$0.011.

Alliance Creative Group was announced today by QualityStocks as having a new audio interview with Alliance Creative Group (OTC: ACGX) COO and general counsel Paul Sorkin. The interview can be heard at www.QualityStocks.net/interview-acgx.php

Alliance Creative Group (ACGX), launched in 2000 as an online marketing company, today operates four key business units pooled together as a strong and profitable source for customized plans and projects for clients spanning multiple industries. The company's key services include creative and design, printing and packaging, direct mailing, product development, supply chain management, project management, event marketing, business consulting and strategic marketing.

Alliance Creative maintains and operates two company websites: alliancecreativegroup.com and Print4aCause.com. Always on the prowl for advancement, the company is also currently in discussions with multiple parties regarding potential mergers or acquisitions, and exploring other equipment and software upgrade options. Additionally, Alliance Creative is seeking a funding partner to help create and accelerate its bigger roll-up business model.

The company’s overarching long-term vision is to create a one-stop-shop printing and packaging company powered by synchronized business divisions with a shared vision to increase overall revenues and profits. This business model leverages vertical integration and cross-promotion between various company sectors and allows Alliance Creative to share resources and maximize efficiencies. These components also improve buying power for the corporation and increase value for both clients and shareholders.

Alliance Creative’s management team boasts decades of production and creative experience that guide company along its trek to generate sales revenue and profits and create a high quality customer experience. Under current management, Alliance Creative in the last three years has recorded more than $30 million in total revenue; $2 million in net income; and has $6 million in total assets in the books. Disclaimer

Alliance Creative Group Company Blog

Alliance Creative Group News:

Alliance Creative Group (ACGX) COO Featured in Exclusive QualityStocks Interview

Alliance Creative Group Reports Strong Second Quarter 2014 Results With 26% Year-Over-Year Revenue Growth and 51% Increase in Gross Profit

Alliance Creative Group (ACGX) Announces Engagement of QualityStocks Investor Relations Services

VistaGen Therapeutics, Inc. (VSTAD)

The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTAD). Today, VistaGen Therapeutics, Inc. closed trading at $15.00, on 100 volume with 1 trade. The stock’s average daily volume over the past 60 days is 303, and its 52-week low/high is $5.00/$17.80.

VistaGen Therapeutics, Inc. (VSTAD) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs

VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.

By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.

Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.

AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.

VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer

VistaGen Therapeutics, Inc. Company Blog

VistaGen Therapeutics, Inc. News:

VistaGen Announces Reverse Stock Split

VistaGen Receives Notice of Allowance for Canadian Patent Expanding Stem Cell Technology Platform

VistaGen Joins HESI's Cardiac Safety Committee and Working Groups

Big Tree Group, Inc. (BIGG)

The QualityStocks Daily Newsletter would like to spotlight Big Tree Group, Inc. (BIGG). Today, Big Tree Group, Inc. closed trading at $0.016, up 33.33%, on 755,400 volume with 45 trades. The stock’s average daily volume over the past 60 days is 570,709, and its 52-week low/high is $0.0105/$0.45.

Big Tree Group, Inc. (BIGG) is an authorized sales agent for thousands of toy manufacturers in China, providing multiple procurement services for international toy distributors and wholesalers. Headquartered in Shantou City, known as the Toy Capital of the world, Big Tree operates a 21,000-square-foot showroom to display its products to thousands of international toy purchasers. The sprawling facility includes an onsite testing laboratory where all toys undergo rigorous testing to ensure both quality and function before reaching the showroom floor.

Big Tree is a “one-stop-shop” for the international sourcing and distribution of toys and other related products. As an authorized agent, Big Tree currently represents more than 8,000 toy manufacturers, offering more than 300,000 varieties of toy products such as remote control toys, digital toys, sports toys, play sets, educational toys, dolls and infant toys. Big Tree conducts its operations through its two fully operating subsidiaries, Big Tree Brunei and Big Tree Shantou.

In 2011, Big Tree began selling its own patented construction toy, the Magic Puzzle (3D). The proprietary Big Tree Magic Puzzle is promoted and distributed solely in the Chinese domestic market, available through Big Tree Shantou’s online store and at several retail locations. The product has been well-received, and Big Tree is also evaluating global marketing and distribution of the Magic Puzzle.

Big Tree’s operations are spearheaded by long-time China toy industry veteran and company CEO Wei Lin, who founded the toy export and import company Shantou Dashu Toy Corp. Ltd. He is supported by a seasoned and experienced management team proficient in operations management, marketing, sales, team management, education and accounting. This leadership team has established an aggressive growth strategy to expand Big Tree’s sales and global product distribution by utilizing its expansive multi-lingual sales team and by leveraging industry contacts to identify strategic mergers and acquisitions, and maximize trade and industry opportunities.

As the world’s leading toy manufacturer and exporter, China produces and distributes two-thirds of the multi-billion dollar toy industry’s global demand. The nation’s manufacturing is highly regional, with 70 percent of toy sales in China generated in the Guangdong province. Strategically located in this province, Big Tree has cultivated an extensive customer base in Asia and Europe and is planning global expansion and distribution, especially in the Americas. Disclaimer

Big Tree Group, Inc. Company Blog

Big Tree Group, Inc. News:

Market Advisors, Inc. Issues Report on Big Tree Group

Big Tree Group Launches New Domestic Online Ecommerce Platform

Big Tree Group Receives Purchase Orders from Costa Rican Retail Chain Valued at Approximately $400,000

LD Holdings, Inc. (LDHL)

The QualityStocks Daily Newsletter would like to spotlight LD Holdings, Inc. (LDHL). Today, LD Holdings, Inc. closed trading at $0.35, up 12.83%, on 4,900 volume with 2 trades. The stock’s average daily volume over the past 60 days is 10,837, and its 52-week low/high is $0.27/$0.78.

LD Holdings, Inc. (LDHL) is a financial and management holding company focused on a niche business opportunity created by changes within the largest demographic group in America. Approximately 25 million small businesses in the United States will be sold in the next 15-20 years as the Baby Boomer generation transitions out of business ownership and into retirement. Employing a multi-faceted approach, LD Holdings seeks to take advantage of this shift by acquiring multiple profitable business entities to produce venture capital returns without the risks associated with venture capital start-ups. Presently, LDHL is targeting 4 sectors: biomedical, tech, entertainment and the green sector.

US consumers spend more than $4 Billion annually in the “do-it-for-me” (DIFM) LCS (Lawn Care Services) market, and $25 Billion+ in the LM (Lawn Maintenance) markets. They also spend another $7 Billion in the structural pest control services (PCO), a major adjacent homeowner service industry. Service category revenues vastly dwarf those of “do-it-yourself” (“DIY”), retail consumer products such as Scotts, Ortho, MiracleGro, et al despite the number of homeowners in each category being roughly equal, therefore far greater revenue per the DIFM customer. The market leaders in both LCS market, TruGreen and the LM market, Brickman/Valley Crest, have comparatively low market shares – 20% and 8% respectively – evidencing the fragmentation of both markets. Both industries are comprised of thousands of smaller firms, many of them Baby Boomer owned businesses, with many being ideal targets for “tuck-in” acquisitions. Brickman (KKR) has recently purchased Valley Crest, which ranked second on the L&L Top 100 list, for multiple times EBIDTA. In contrast, the LD Holdings business model expects to acquire the green sectors’ targeted businesses for less than EBIDTA.

Recently LD Holdings secured a $10 million (line of credit) from a qualified institution to pursue these acquisitions. This secured line of credit facility will enable the company to complete its first three acquisition targets which will total $16 million sales and $2.3 million EBITDA. The company has signed a letter of intent to close on its first company in the green sector in the 3rd quarter of this year.

LD Holdings’ five-year plan is to merge its acquired entities into cohesive business units to generate revenues through organic growth to exceed $30 Million during the first 5 years. The 5-year plan also includes additional acquisitions beyond the initial platforms and some early LM (Lawn Maintenance) “tuck-in” additions as well. Management firmly believes that the enterprise can be readily grown to $60 Million plus with LCS (Lawn Care Services) greenfield expansion (replicating the platform operating model in additional cities/geographies), franchising, branchising, and licensing. The $60 Million plus is only reflected in the company’s green sector portion of its operations.

LD Holdings is positioned to capitalize on the changing dynamics of the Baby Boomer generation while enabling investors to diversify their investment by owning several companies with increased valuations, in various sectors under one umbrella, rather than just one company at a time. Disclaimer

LD Holdings, Inc. Company Blog

LD Holdings, Inc. News:

LD Holdings Signs Joint Venture With Internet Marketing Consortium (IMC)

LD Holdings in Joint Venture Talks With Internet Marketing Consortium

LD Holdings Targets Green Sector

Pan Global Corp. (PGLO)

The QualityStocks Daily Newsletter would like to spotlight Pan Global Corp. (PGLO). Today, Pan Global Corp. closed trading at $0.018, up 16.88%, on 343,292 volume with 23 trades. The stock’s average daily volume over the past 60 days is 686,830, and its 52-week low/high is $0.015/$0.96.

Pan Global Corp. (PGLO) is focused on building the world’s green economy by developing, building, owning, and operating the necessary infrastructure. Current opportunities are currently concentrated on developing projects in India, specifically in the areas of hydro-power generation, solar PV, geo-thermal, sustainable agriculture, and green construction.

The India growth story is frequently compared to China, which has sustained above-average annual growth for three decades, whereas India’s take-off growth began at a later stage. During the last decade, India’s growth has averaged approximately 8% per year. India is poised for high GDP growth that will be sustained for decades to come.

Within the Indian market there are available various government-backed incentives programs, including those which provide direct tariff subsidies as well as market-based tariff support through renewable energy credits. Assessing project viability on a case by case basis, Pan Global seeks to invest in projects both as owner-developers and/or as partners with other developers.

Pan Global’s business strategy is an extension of the company’s commitment to improve human well-being and social equity, while significantly reducing environmental risks and ecological scarcities. By developing a series of highly environmentally sustainable and high ROI projects, Pan Global aims to accelerate business growth. Disclaimer

Pan Global Corp. Company Blog

Pan Global Corp. News:

Pan Global, Corp. Comments on Industry Report That the India Renewable Energy Market Opportunity Is Worth USD $10.5 Billion by 2017

Pan Global, Corp. Shareholder Update: Small-Hydro Plant Connected to Power Grid in Northern India

Pan Global, Corp. Increases Equity Stake in 5.7 MW Small-Hydro Plant in Northern India


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Growing Stocks Reports




007 Stock Chat

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251